FDA pharmacologic class
Interleukin-23 Antagonist
7 medicines are in FDA's class of interleukin-23 antagonists: ustekinumab (Stelara), risankizumab (Skyrizi), mirikizumab (Omvoh), ustekinumab-aekn (Selarsdi), guselkumab (Tremfya), ustekinumab-srlf (Imuldosa) and tildrakizumab (Ilumya). 0 of the 7 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is tremfya 100 mg/ml syringe at $14,728.91 per mL (NADAC).
Which medicines are interleukin-23 antagonist?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Ustekinumab | Wezlana, Pyzchiva, Steqeyma | none listed | $29,874.45 per mL 45 mg/0.5 mL syringe | No | No current entry | 0 |
| Risankizumab | Skyrizi | none listed | $22,774.36 per mL 150 mg/mL pen | No | No current entry | 0 |
| Mirikizumab | Omvoh | none listed | n/a | No | A presentation being discontinued | 0 |
| Ustekinumab-aekn | Selarsdi | none listed | n/a | No | No current entry | 0 |
| Guselkumab | Tremfya | none listed | $14,728.91 per mL 100 mg/mL syringe | No | No current entry | 1 |
| Ustekinumab-srlf | Imuldosa | none listed | n/a | No | No current entry | 1 |
| Tildrakizumab | Ilumya | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price